|
Corporate / Organization
Organization
PCAS Profile 2 fields of activity Pharmaceutical Synthesis:
Fine Speciality Chemicals:
The PCAS group is focused on several markets in Fine Chemicals. Fine Chemistry, dedicated to Pharmaceutical Synthesis, consists of developing and producing complex molecules from basic chemical substances in a number of successive reactions or « steps », each one may call on a different technology. Fine Speciality Chemicals is the manufacture of products with well-defined properties for a diversified and industrial customer base. PCAS adopts two approaches whilst working with its customers in these markets, by either providing proprietary products resulting from research within the Group or being based on a more specific relationship built up through collaboration contracts, initially at Research & Development stage, with an objective to manufacture. PCAS’s expertise, acquired over nearly 50 years, enables the company to devise and produce molecules, as well as synthesis intermediates, with a high technological added-value. PCAS is today one of the world market’s unquestionable players, following a phase of external growth and integration of its acquisitions which has enabled it to grow its production capacity and to extend its technological diversity. More often than not, its customers are world leaders in their respective markets. PCAS establishes relations based on long-term partnerships, founded on confidence and proximity, and completely respecting ethical codes and confidentiality. PCAS’s strength is to work hand-in-hand with the customer through all the steps of a project, whilst pulling on its strong R&D potential and its expertise in the main key technologies. Its flexible industrial equipment is devised in order to respond to three imperatives: product quality, process optimisation, reactivity, with a constant concern for safety and sustainable development. PCAS adopts a « service-based » approach which includes the completion of regulatory files, a necessary step required for market product launch which has become a strategic element of differentiation. Thanks to its customer focused organisation, PCAS adapts to the requirements and details of a project with flexibility, whilst taking on certain key steps or the entire development cycle. PCAS’s catalogue product range is extended to anticipate the needs of its partners. It supports the development of new markets, notably in Pharmaceutical Synthesis, the emergence of biotechnology start-ups and the increase in strength of generics, in which PCAS already has a sound experience and a portfolio enriched with molecules. PCAS is a reliable and dependable supplier to its domestic and international customers, which is rare in the scope of an unquestionable code of ethics. Always looking to adapt to its customer requirements, PCAS invested in the field of biotechnologies in 2006. At that time, PCAS Biosolution, a joint venture with Protéus, was created with the aim of developing and industrialising new synthesis routes for intermediates and active pharmaceutical ingredients. In order to strengthen this partnership, PCAS invested in Protéus capital and recently increased its stake to 42.9%, enabling Protéus to widen its range of services into the development of recombinant Proteins for bio-industries in health, chemicals, environmental and bioenergy sectors.
Legal Structure 
|
|||||||||
